Suscribirse

Effects of probiotic supplementation on glycaemic control and lipid profiles in gestational diabetes: A randomized, double-blind, placebo-controlled trial - 22/09/16

Doi : 10.1016/j.diabet.2016.04.009 
M. Karamali a, F. Dadkhah a, M. Sadrkhanlou a, M. Jamilian b, S. Ahmadi a, c, M. Tajabadi-Ebrahimi e, P. Jafari e, Z. Asemi f,
a Department of gynecology and obstetrics, school of medicine, Iran university of medical sciences, Tehran, Iran 
b Endocrinology and metabolism research center, department of gynecology and obstetrics, school of medicine, Arak university of medical sciences, Arak, Iran 
c Department of gynecology and obstetrics, school of medicine, Bushehr university of medical sciences, Bushehr, Iran 
d Faculty member of science department, science faculty, Islamic Azad university, Tehran Central branch, Tehran, Iran 
e Department of microbiology, science faculty, Islamic Azad university, Arak branch, Arak, Iran 
f Research center for biochemistry and nutrition in metabolic diseases, Kashan university of medical sciences, Kashan, Iran 

Corresponding author. Tel.: +98 31 554 633 78; fax: +98 31 554 633 77.

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Abstract

Background

To our knowledge, data on the effects of probiotic supplementation on glycaemic control and lipid concentrations in patients with gestational diabetes mellitus (GDM) are scarce.

Aim

The aim of the present study was to determine the effects of probiotic supplementation on glycaemic control and lipid profiles in GDM patients.

Methods

Sixty pregnant women with GDM, primigravida and aged 18–40years, were divided into two groups to receive either probiotic capsules (n=30) or a matching placebo (n=30) in this randomized double-blind, placebo-controlled trial. The patients in the probiotic group took a daily capsule that contained three viable freeze-dried strains: Lactobacillus acidophilus (2×109CFU/g), Lcasei (2×109CFU/g) and Bifidobacterium bifidum (2×109CFU/g) for 6weeks. The placebo group took capsules filled with cellulose for the same time period. Fasting blood samples were taken at the beginning and end of the study to quantify the relevant markers.

Results

After 6weeks of intervention, probiotic supplementation vs a placebo resulted in significant decreases in fasting plasma glucose (−9.2±9.2mg/dL vs +1.1±12.2mg/dL, P<0.001), serum insulin levels (−0.8±3.1μIU/mL vs +4.5±10.6μIU/mL, P=0.01), homoeostasis model assessment (HOMA) for insulin resistance (−0.4±0.9 vs +1.1±2.5, P=0.003) and HOMA for β-cell function (+1.1±9.8 vs +18.0±42.5, P=0.03), and a significant increase in the quantitative insulin sensitivity check index (+0.007±0.01 vs −0.01±0.02, P=0.007). In addition, significant decreases in serum triglycerides (−1.6±59.4mg/dL vs +27.1±37.9mg/dL, P=0.03) and VLDL cholesterol concentrations (−0.3±11.9mg/dL vs +5.4±7.6mg/dL, P=0.03) were seen following supplementation with the probiotics compared with the placebo. However, no significant changes in other lipid profiles were seen with the intervention.

Conclusion

Overall, the results of our study have demonstrated that taking probiotic supplements for 6weeks in patients with GDM had beneficial effects on glycaemic control, triglycerides and VLDL cholesterol concentrations, although there was no effect on other lipid profiles.

El texto completo de este artículo está disponible en PDF.

Keywords : Gestational diabetes mellitus, Insulin resistance, Lipid profiles, Probiotic supplementation


Esquema


© 2016  Elsevier Masson SAS. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 42 - N° 4

P. 234-241 - septembre 2016 Regresar al número
Artículo precedente Artículo precedente
  • Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics
  • A.J. Scheen
| Artículo siguiente Artículo siguiente
  • Sustained effects of a protein and lipid preload on glucose tolerance in type 2 diabetes patients
  • D. Tricò, E. Filice, S. Baldi, S. Frascerra, A. Mari, A. Natali

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.